Major Depressive Disorder is one of the most common psychiatric disorders, affecting millions of people worldwide. Antidepressant drugs are widely used, but 50% of depressed patients receiving these medications will relapse, and 30% are drug resistant. Thus, new targets for antidepressants are needed. Converging evidence indicates an important role for depression-associated changes in hippocampal circuitry. For example, depressed humans and animal models of depression have smaller hippocampi, and decreased activity-dependent genes and processes, like hippocampal dentate gyrus (DG) neurogenesis. Notably, antidepressant drugs and non-pharmacological treatments like electroconvulsive treatment ameliorate these changes. From such work, a new framework for discovery of novel antidepressants has emerged: find treatments that recalibrate depression-linked dysfunctional neural circuits and behavior. Indeed, other approaches to stimulate neural circuits - such as deep brain stimulation (DBS) - can reverse depression-related symptoms and neuropathology, particularly in the hippocampus. Strikingly, in the context of depression, DBS has only been targeted to non-hippocampal brain regions. DBS of the main hippocampal input - the entorhinal cortex (Ent) via the perforant path (PP) - has proven physiologically beneficial in other contexts: it enhances memory in humans and memory and DG neurogenesis in laboratory animals. However, it remains unknown if stimulation of the PP will produce antidepressant-like behaviors. For this exploratory and developmental R21 project, we will test the hypothesis that controlled activation of PP to DG is antidepressive. This hypothesis emerges from our pilot data showing: a) stress and depression are linked to greater PP levels of TRIP8b, a brain-specific auxiliary subunit of HCN channels; b) germline knockout of TRIP8b - which is antidepressive - increases DG neurogenesis; and c) PP disinhibition (de-repression of Ent neuronal excitability via knockdown of TRIP8b) increases DG neurogenesis and is antidepressive. We also provide d) feasibility data that we can chemogenetically-stimulate DG via PP activation. Based on these data, we will:
Aim 1 : Determine whether molecular-based PP disinhibition promotes antidepressive behavior using viral-mediated KD of TRIP8b in the PP and a battery of depression-linked and cognitive behaviors;
and Aim 2 : Determine whether chemogenetic stimulation of PP activity drives antidepressive behavior using DREADDs (Designer Receptors Exclusively Activated by Designer Drugs) to mediate neuronal activity and behavior. While the aims proposed here involve considerable risk, they are logical and highly feasible given the large amount of pilot data and the published ability of PP stimulation to improve hippocampal cognitive function. This project is in an early and conceptual stage, and has focused, behavioral outcomes, making it ideal for the R21 mechanism. Even if the hypothesis is incorrect, the experimental design ensures that the collected data will advance our knowledge of brain circuits contributing to affect and cognition.

Public Health Relevance

Major depressive disorder is the most common mental illness, yet many people prescribed antidepressants will relapse or be unresponsive to the beneficial effects of these drugs or non-pharmaceutical therapies. A current theory of depression proposes it is a 'circuitopathy', marked by dysfunctional brain circuits, and indeed evidence suggests depression can indeed be treated with magnetic or electrical stimulation applied to discrete parts of the brain. In this exploratory grant application, we propose to explor whether stimulation of a memory- related brain circuit can also combat the behavioral symptoms of depression.

Agency
National Institute of Health (NIH)
Institute
National Institute of Mental Health (NIMH)
Type
Exploratory/Developmental Grants (R21)
Project #
5R21MH107945-02
Application #
9121624
Study Section
Neurobiology of Motivated Behavior Study Section (NMB)
Program Officer
Simmons, Janine M
Project Start
2015-08-15
Project End
2017-06-30
Budget Start
2016-07-01
Budget End
2017-06-30
Support Year
2
Fiscal Year
2016
Total Cost
Indirect Cost
Name
University of Texas Sw Medical Center Dallas
Department
Psychiatry
Type
Schools of Medicine
DUNS #
800771545
City
Dallas
State
TX
Country
United States
Zip Code
75390
Yun, Sanghee; Reynolds, Ryan P; Petrof, Iraklis et al. (2018) Stimulation of entorhinal cortex-dentate gyrus circuitry is antidepressive. Nat Med 24:658-666
Whoolery, Cody W; Walker, Angela K; Richardson, Devon R et al. (2017) Whole-Body Exposure to 28Si-Radiation Dose-Dependently Disrupts Dentate Gyrus Neurogenesis and Proliferation in the Short Term and New Neuron Survival and Contextual Fear Conditioning in the Long Term. Radiat Res 188:532-551
Celen, Cemre; Chuang, Jen-Chieh; Luo, Xin et al. (2017) Arid1b haploinsufficient mice reveal neuropsychiatric phenotypes and reversible causes of growth impairment. Elife 6:
Mendoza, Matthew L; Anderson, Ethan M; Kourrich, Saïd et al. (2016) A NAc for Spinal Adjustments After Cocaine or Stress. Biol Psychiatry 79:872-4
Yun, Sanghee; Reynolds, Ryan P; Masiulis, Irene et al. (2016) Re-evaluating the link between neuropsychiatric disorders and dysregulated adult neurogenesis. Nat Med 22:1239-1247
Yun, Sanghee; Donovan, Michael H; Ross, Michele N et al. (2016) Stress-Induced Anxiety- and Depressive-Like Phenotype Associated with Transient Reduction in Neurogenesis in Adult Nestin-CreERT2/Diphtheria Toxin Fragment A Transgenic Mice. PLoS One 11:e0147256
Petrik, David; Latchney, Sarah E; Masiulis, Irene et al. (2015) Chromatin Remodeling Factor Brg1 Supports the Early Maintenance and Late Responsiveness of Nestin-Lineage Adult Neural Stem and Progenitor Cells. Stem Cells 33:3655-65
Latchney, Sarah E; Jiang, Yindi; Petrik, David P et al. (2015) Inducible knockout of Mef2a, -c, and -d from nestin-expressing stem/progenitor cells and their progeny unexpectedly uncouples neurogenesis and dendritogenesis in vivo. FASEB J 29:5059-71